Avalo Therapeutics (NASDAQ:AVTX) Given New $10.00 Price Target at BTIG Research

Avalo Therapeutics (NASDAQ:AVTX) had its price objective dropped by equities researchers at BTIG Research to $10.00 in a research report issued to clients and investors on Friday, MarketBeat.com reports. The firm presently has a “buy” rating on the stock. BTIG Research‘s target price suggests a potential upside of 43.35% from the company’s previous close.

A number of other brokerages also recently weighed in on AVTX. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Avalo Therapeutics in a research report on Wednesday, September 16th. HC Wainwright reaffirmed a “neutral” rating on shares of Avalo Therapeutics in a research report on Friday. Guggenheim reaffirmed a “neutral” rating on shares of Avalo Therapeutics in a research report on Friday. Leerink Partners started coverage on Avalo Therapeutics in a research report on Monday, July 6th. They set an “outperform” rating and a $38.00 price objective on the stock. Finally, Weiss Ratings raised Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Ten investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $39.10.

Avalo Therapeutics Trading Down 6.4%

Shares of Avalo Therapeutics stock traded down $0.47 during trading on Friday, hitting $6.98. 828,884 shares of the stock traded hands, compared to its average volume of 1,268,891. The firm has a market cap of $374.12 million, a P/E ratio of -1.60 and a beta of 0.68. Avalo Therapeutics has a 52-week low of $6.72 and a 52-week high of $24.27. The stock’s fifty day simple moving average is $16.30 and its 200 day simple moving average is $16.67.

Avalo Therapeutics (NASDAQ:AVTX) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). As a group, equities analysts expect that Avalo Therapeutics will post -2.95 EPS for the current year.

Insider Activity

In other news, CFO Christopher Sullivan sold 12,394 shares of Avalo Therapeutics stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $16.33, for a total value of $202,394.02. Following the sale, the chief financial officer directly owned 39,900 shares of the company’s stock, valued at $651,567. The trade was a 23.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 24,258 shares of company stock valued at $415,434 over the last quarter. Insiders own 4.46% of the company’s stock.

Institutional Trading of Avalo Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Braidwell LP acquired a new stake in shares of Avalo Therapeutics in the second quarter worth approximately $30,107,000. Affinity Asset Advisors LLC boosted its stake in Avalo Therapeutics by 27.6% during the first quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after buying an additional 289,786 shares during the last quarter. Seven Fleet Capital Management LP boosted its stake in Avalo Therapeutics by 34.3% during the second quarter. Seven Fleet Capital Management LP now owns 770,765 shares of the company’s stock worth $14,244,000 after buying an additional 196,882 shares during the last quarter. Bank of America Corp DE boosted its stake in Avalo Therapeutics by 3.5% during the first quarter. Bank of America Corp DE now owns 643,000 shares of the company’s stock worth $9,600,000 after buying an additional 21,650 shares during the last quarter. Finally, Squarepoint Ops LLC boosted its stake in Avalo Therapeutics by 624.9% during the second quarter. Squarepoint Ops LLC now owns 589,245 shares of the company’s stock worth $10,889,000 after buying an additional 507,960 shares during the last quarter. 87.06% of the stock is owned by institutional investors and hedge funds.

More Avalo Therapeutics News

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: Wedbush maintained an “outperform” rating while lowering its price target from $34 to $22. The revised target still implies substantial upside from recent trading levels. Wedbush Adjusts Avalo Therapeutics Price Target
• Positive Sentiment: BTIG Research retained a “buy” rating and set a $10 price target, indicating potential upside despite reducing its valuation expectations. BTIG Research Avalo Therapeutics Ratings
• Neutral Sentiment: Guggenheim reaffirmed its “neutral” rating, suggesting limited conviction in the near-term risk-reward profile. Guggenheim Avalo Therapeutics Ratings
• Neutral Sentiment: Trading in AVTX was temporarily paused under a limit-up/limit-down (LULD) volatility halt, highlighting unusually sharp trading activity but not representing a fundamental company announcement.
• Negative Sentiment: HC Wainwright downgraded Avalo from “buy” to “neutral,” while separately reaffirming a neutral rating in another update. The change signals reduced confidence in the stock’s near-term appreciation potential. HC Wainwright Downgrades Avalo Therapeutics
• Negative Sentiment: Analysts also cut price targets, including Wedbush’s reduction, reflecting lower valuation assumptions. Reports that AbbVie’s phase 3 HS results may strengthen a competing treatment add a significant pipeline and commercialization risk for Avalo. AbbVie Phase 3 Data Subdue Avalo Shares

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development programs are intended to address conditions with significant unmet medical needs.

Avalo’s lead product candidate is AVTX-009, a fully human monoclonal antibody designed to inhibit interleukin-1 beta, an inflammatory cytokine involved in several immune-related disorders. The candidate is being evaluated for potential treatment of hidradenitis suppurativa, a chronic inflammatory skin disease, and other inflammatory conditions.

The company was formerly known as Cerecor Inc and adopted the Avalo Therapeutics name in 2021.